Mechanism of Yin-Qin oral liquid for treatment of COVID-19 based on network pharmacology

Update:Oct. 16, 2020Total Views:1442Total Downloads:430 DownloadMobile

Author: Shi-Liang JI 1 Li-Ping HE 2 Dong-Kai GUO 1 Wei WANG 3 Hui CHEN 3 Yi-Guo JIANG 1 Cheng WANG 1*

Affiliation: 1. Laboratory of Clinical Pharmacy, The Affiliated Suzhou Science and Technology Town Hospital of Nanjing Medical University, Suzhou 215153, Jiangsu Province, China 2. Suzhou Tianling Chinese Herbal Medicine Co. Ltd, Suzhou 215000, Jiangsu Province, China 3. Southwest University College of Pharmaceutical Science and Chinese Medicine, Luzhou 646000, Sichuan Province, China

Keywords: Yin-Qin oral liquid COVID-19 Target protein interaction Signaling pathway

DOI:10.12173/j.issn.1004-5511.2020.05.03

Reference:Ji SL, He LP, Guo DK, Wang W, Chen H, Jiang YG, Wang C. Mechanism of Yin-Qin oral liquid for treatment of COVID-19 based on network pharmacology [J]. Yixue Xinzhi Zazhi, 2020, 30(5): 345-354. DOI: 10.12173/j.issn.1004-5511.2020.05.03.[Article in Chinese]

  • Abstract
  • Full-text
  • Figures and Tables
  • References
Abstract

Objective  To explore the potential active components and molecular mechanism of Yin-Qin oral liquid(YQOL) for treatment of pediatric coronavirus pneumonia (COVID-19). Methods  With the help of TCMSP and BATMAN-TCM platform obtaining honeysuckle, scutellaria baicalensis, bupleurum, cicada slough active chemical constituents and action targets. Through UniProt, GeneCards database convert Target and gene, and then Cytoscape3.7.2 was used to construct the “active-target” networks and perform topological analysis, The core targets were analyzed by GO and KEGG functional enrichment analysis by R software. Results  The network analysis indicated that 56 active ingredients affected 266 key target proteins, and the key targets involve PTGS1, GSK3β, NCOA2, ESR1, ESR2, etc. The function enrichment analysis of GO was involved in 237 biological processes(BP), 54 cell components (CC), and 65 molecular function (MF). There are 66 items enriched in KEGG pathway, involving Neuroactive ligand-receptor interaction, cancer and cAMP signaling pathway, etc. Molecular docking revealed that bupleurum, scutellaria baicalensis and honeysuckle contained more potential anti-covid-19 active ingredients, and Bupleurum saponins (A, D), baicalin and isopterin have the strongest affinity. Conclusion  The active compounds in YQOL may interfere multiple pathways through antivirus, inhibition of inflammatory factors and regulation of immunity and provide a research direction for elucidation of the anti-COVID-19 pharmacological mechanism of YQOL.

Full-text
  Please download the PDF version to read the full text: download
References

1.      苏石, 李小承, 蒿花, 等.新型冠状病毒的研究进展[J]. 西安交通大学学报(医学版), 2020, 41(4): 479-482, 496. DOI: 10.7652/jdyxb202004002. [Su S, Li XC, Hao H, et al. Advances in research on SARS-CoV-2[J]. Journal of Xi'an Jiaotong University(Medical Sciences), 2020, 41(4): 479-482, 496.]

2.      李衍达, 张文晋, 赵振宇, 等. 中医诊治SARS的经验对新型冠状病毒肺炎的启示[J]. 天津中医药, 2020, 37(5): 490-495. DOI: 10.11656/j.issn.1672-1519.2020.05.03.[Li YD, Zhang WJ, Zhao ZY, et al. Inspiration of diagnosis and treatment of SARS with traditional Chinese medicine on novel coronavirus pneumonia[J]. Tianjin Journal of Traditional Chinese Medicine, 2020, 37(5): 490-495.]

3.      靳英辉, 蔡林, 程真顺, 等. 新型冠状病毒(2019-nCoV)感染的肺炎诊疗快速建议指南(完整版)[J].医学新知, 2020, 30(1): 35-64. DOI: 10.12173/j.issn.1004- 5511.2020.01.09. [Ji YH, Cai L, Cheng ZS, et al. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (Full version)[J]. Yixue Xinzhi Zazhi, 2020, 30(1): 35-64.]

4.      仇毅. 金蝉口服液联合头孢美唑治疗小儿轻中度社区获得性呼吸道感染临床研究[J]. 海峡药学, 2017, 29(7): 161-163. DOI: 10.3969/j.issn.1006-3765.2017.07.080. [Qiu Y. Clinical study on treatment of mild to moderate community acquired respiratory tract infection in children with jin-chan oral liquid combined with cefmeazole[J]. Strait Pharmaceutical Journal, 2017, 29(7): 161-163.]

5.      周政, 朱春胜, 张冰. 基于数据挖掘的中医药治疗新型冠状病毒肺炎用药规律研究[J].中国中药杂志, 2020, 45(6): 1248-1252. DOI: 10.19540/j.cnki.cjcmm.20200220.502. [Zhou Z, Zhu CS, Zhang B. Study on medication regularity of traditional Chinese medicine in treatment of COVID-19 based on data mining[J]. China Journal of Chinese Materia Medica, 2020, 45(6): 1248-1252.]

6.      Liu JF, Hu AN, Zan JF, et al. Network Pharmacology Deciphering Mechanisms of Volatiles of Wendan Granule for the Treatment of Alzheimer's Disease[J]. Evid Based Complement Alternat Med, 2019, 2019: 7826769. DOI: 10.1155/2019/7826769.

7.      宗阳, 丁美林, 贾可可, 等. 基于网络药理学和分子对接法探寻达原饮治疗新型冠状病毒肺炎(COVID-19)活性化合物的研究[J].中草药, 2020, 51(4): 836-844. DOI: 10.7501/j.issn.0253-2670.2020.04.002. [Zong Y, Ding ML, Jia KK, et al. Exploring active compounds of Da-Yuan-Yin in treatment of COVID-19 based on network pharmacology and molecular docking method[J]. Chinese Traditional and Herbal Drugs, 2020, 51(4): 836-844.]

8.      Ru J, Li P, Wang J, et al. TCMSP: a database of systems pharmacology for drug discovery from herbal medicines[J]. J Cheminform 2014, 6: 13. DOI: 10.1186/1758-2946-6-13.

9.      Liu Z, Guo F, Wang Y, et al. BATMAN-TCM: a bioinformatics analysis tool for molecular mechanism of Traditional Chinese Medicine[J]. Sci Rep, 2016, 6: 21146. DOI: 10.1038/srep21146.

10.    Zhou Y, Zhou B, Pache L, et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets[J]. Nat Commun, 2019, 10(1): 1-10. DOI: 10.1038/s41467-019-09234-6.

11.    陈嘉源, 施劲松, 丘栋安, 等. 2019新型冠状病毒基因组的生物信息学分析[J]. 生物信息学, 2020, 18(2): 96-102. DOI: 1012113/202001007. [Chen JY, Shi JS, Qiu DA, et al. Bioinformatics analysis of the 2019 novel coronavirus genome[J]. Chinese Journal of Bioinformatics, 2020, 18(2): 96-102.]

12.    沈黎, 王诚, 郝创利, 等. 金蝉口服液治疗小儿呼吸道合胞病毒肺炎的有效性与安全性[J]. 中国新药与临床杂志, 2017, 36(7): 409-413. DOI: 10.14109/j.cnki.xyylc.2017.07.008. [Shen L, Wang C, Hao CL, et al. Efficacy and safety of Jin-chan oral liquid in treatment of infants with respiratory syncytial virus pneumonia[J]. Chinese Journal of New Drugs and Clinical Remedies, 2017, 36(7): 409-413.]

13.    Holshue ML, DeBolt C, Lindquist S, et al. First Case of 2019 Novel Coronavirus in the United States[J]. N Engl J Med, 2020, 382(10): 929-936. DOI: 10.1056/NEJMoa2001191.

14.    刘菊, 崔瑛, 白明学, 等. 基于中医药防治新型冠状病毒肺炎的用药探析[J]. 中草药, 2020, 51(4): 860-865. [Liu J, Cui Y, Bai MX, et al. Application of traditional Chinese medicine in prevention and treatment of COVID-19[J]. Chinese Traditional and Herbal Drugs, 2020, 51(4): 860-865.]

15.    Zhuang MW, Cheng Y, Zhang J, et al. Increasing host cellular receptor-angiotensin-converting enzyme 2 expression by coronavirus may facilitate 2019-nCoV (or SARS-CoV-2) infection [published online ahead of print, 2020 Jun 4][J]. J Med Virol, 2020, 10.1002/jmv.26139. DOI: 10.1002/jmv.26139

16.    孟凡翠, 汤立达. 中药网络药理学研究中存在的问题与发展展望[J]. 中草药, 2020, 51(8): 2232-2237. DOI: 10.7501/j.issn.0253-2670.2020.08.034. [Meng FC, Tang LD. Challenges and prospect in research of Chinese materia medica network pharmacology[J]. Chinese Traditional and Herbal Drugs, 2020, 51(8): 2232-2237.]

Hot Papers